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Abstract
Background: Although many drugs are available for the treatment of gastric ulcers, often these drugs are
ineffective. Many antidepressant drugs have been shown to have antiulcer activity in various models of
experimental ulcer. One such drug, the antidepressant mirtazapine, has been reported to have an antiulcer
effect that involves an increase in antioxidant, and a decrease in oxidant, parameters. To date, however,
there is no information available regarding the antiulcer activity for a similar antidepressant, fluvoxamine.
This study aimed to investigate the antiulcer effects of fluvoxamine and to determine its relationship with
antioxidants.
Methods: Groups of rats fasted for 24 h received fluvoxamine (25, 50, 100 and 200 mg/kg), ranitidine (50
mg/kg) or distilled water by oral gavage. Indomethacin (25 mg/kg) was orally administered to the rats as
an ulcerative agent. Six hours after ulcer induction, the stomachs of the rats were excised and an ulcer
index determined. Separate groups of rats were treated with the same doses of fluvoxamine and ranitidine,
but not with indomethacin, to test effects of these drugs alone on biochemical parameters. The stomachs
were evaluated biochemically to determine oxidant and antioxidant parameters. We used one-way
ANOVA and least significant difference (LSD) options for data analysis.
Results: The 25, 50, 100 and 200 mg/kg doses of fluvoxamine exerted antiulcer effects of 48.5, 67.5, 82.1
and 96.1%, respectively, compared to the control rat group. Ranitidine showed an 86.5% antiulcer effect.
No differences were observed in the absence of indomethacin treatment for any dose of fluvoxamine or
for ranitidine. The levels of antioxidant parameters, total glutathione and nitric oxide, were increased in
all fluvoxamine groups and in the ranitidine group when compared with the indomethacin-only group. In
addition, fluvoxamine and ranitidine decreased the levels of the oxidant parameters, myeloperoxidase and
malondialdeyhyde, in the stomach tissues of the rats when compared to indomethacin group.
Conclusion: We conclude that fluvoxamine has antiulcer effects, and that these occur by a mechanism
that involves activation of antioxidant parameters and inhibition of some toxic oxidant parameters.
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Background
Steroid and non-steroidal drugs, cigarettes, alcohol usage,
trauma, sepsis, shock, Helicobacter pylori, and stress have
been shown to contribute to gastric ulcer formation [1-4].
Stress is one of the more aggressive factors and underlies
many other diseases apart from ulcers, for example,
depression. Stress is one of the most commonly used
methods to produce ulcer models [5,6]. Depression,
accompanied by psychotic and somatic symptoms, is
present in most patients with gastro intestinal system
(GIS) ulcers [7]. Of interest to the current study are reports
that show that certain antidepressants can also have anti-
ulcerative effects [8].
The earliest reported use of antidepressants for gastro
intestinal (GI) disease was the use of tricyclic antidepres-
sants (TCAs) for the treatment of peptic ulcer disease [8].
Antiulcer effects of some other antidepressant drugs such
as fluoksetin, bupropion, dothiepin, maprotiline, mian-
serin, trimipramine, idazoksan, monoaminooxidase -B
(MAO-B) inhibitors, imipramine, amiltriptiline, mirtaza-
pine, among others, have since been reported [9-16]. An
increased vulnerability to depression [17] and anxiety
[18] in experimental animals is paralleled with ulcer
development and the same holds true for humans
[19,20]. Moreover, classic antidepressants [21,22] and
anxiolytics [23,24] can significantly reduce stress ulcer for-
mation, perhaps to a greater extent than that seen with tra-
ditional therapies such as cimetidine and antacids [25].
Fluvoxamine, a selective serotonin reuptake inhibitor
(SSRI) drug, inhibits the CYP 1A2 enzyme [26], which is
known to produce reactive oxygen species [27]. Neverthe-
less, etiologic factors are ambiguous in approximately
60%–80% of ulcer diseases, and the physiopathologic
conditions in the process of illness are similar [1]. For
example, increased levels of reactive oxygen species (ROS)
are indicated in the mechanism of both stress and
indomethacin-induced gastric damage [28]. The impor-
tant roles of oxygen-derived ROS and lipid peroxides
(LPO) in acute gastric lesions, which are induced by non-
steroidal anti-inflammatory drugs (NSAIDs) such as
indomethacin, have been supported by experimental data
[29,30].
While some SSRI drugs have been reported to enhance
upper GIS bleeding when combined with NSAIDs [31-
33], fluvoxamine may be beneficial for the GI tract as a
consequence of its inhibitory effect on the CYP 1A2
enzyme, and resultant reduction in oxidative damage. The
importance of increasing antioxidant parameters and
decreasing oxidant parameters in the antiulcer effect
mechanism of mirtazapine, an antidepressant drug, has
also been reported [16]. To date, however, there is no
information available regarding the antiulcer activity of
fluvoxamine. The aim of the current study was therefore to
examine the effects of fluvoxamine in an indomethacin-
induced ulcer model on rats, and to evaluate its effects on
oxidant and antioxidant parameters in rat stomach tissue.
Methods
Animals
The animals were obtained from the Medical Experimen-
tal Research Centre, Atatürk University. A total of 78 male
albino Wistar rats, weighing between 190 and 210 g, were
used for this study. The animals were fed under normal
conditions (22°C) in separate groups. Animal experi-
ments were performed in accordance with national guide-
lines for the use and care of laboratory animals and were
approved by the local animal care committee of Atatürk
University.
Chemicals
All chemicals for laboratory experimentation were pur-
chased from Sigma Chemical (Germany). Indomethacin,
fluvoxamine, ranitidine, and thiopental sodium were
obtained from Deva Holding-Turkey, Solvay-Turkey,
Fako-Turkey and IE Uluagay-Turkey respectively.
Indomethacin-induced ulcer test
The antiulcer activities of fluvoxamine have been investi-
gated in an indomethacin-induced ulcer models in rats
[34]. Fluvoxamine in doses of 25, 50, 100 or 200 mg/kg
[35,36] and ranitidine in a 50-mg/kg dose were adminis-
tered to 24-hour fasted rat groups by oral gavage. An equal
volume of distilled water was administered to the control
group as a vehicle. Five minutes after drug administration,
all groups received 25 mg/kg indomethacin orally. Six
hours after indomethacin administration, all rat groups
were killed with a high dose of thiopental sodium (50 mg/
kg, intra-peritoneal). The stomachs of all of the rats were
excised. Ulcer areas on the surfaces of the stomachs were
examined macroscopically and measured on square-mil-
limeter paper. The results obtained from the fluvoxamine
groups were evaluated by comparing them with those of
the control and ranitidine groups. Then, all of the stom-
achs (fluvoxamine groups, negative control group, posi-
tive control group, and intact groups) were kept in -80°C
for biochemical investigation of glutathione (GSH), nitric
oxide (NO), myeloperoxidase (MPO) and malondialde-
hyde (MDA) levels.
The groups used for this ulcer experiment can be summa-
rized as follows:
Group 1: Fluvoxamine 25 mg/kg + indomethacin 25 mg/
kg
Group 2: Fluvoxamine 50 mg/kg + indomethacin 25 mg/
kgBMC Gastroenterology 2009, 9:36 http://www.biomedcentral.com/1471-230X/9/36
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Group 3: Fluvoxamine 100 mg/kg + indomethacin 25 mg/
kg
Group 4: Fluvoxamine 200 mg/kg + indomethacin 25 mg/
kg
Group 5: Ranitidine 50 mg/kg + indomethacin 25 mg/kg
Group 6: Distilled water+ indomethacin 25 mg/kg
Group 7: Intact group which received only distilled water.
In addition to this ulcer experiment, we evaluated
whether administration of fluxoxamine (25, 50 100 and
200 mg/kg doses) and ranitidine (50-mg/kg) to 24 hour
fasted rats, in the absence of an indomethacin treatment,
would also change biochemical parameters. For this pur-
pose, a total of 36 rats were fasted for 24 hour with free
access to water. Then the rats were divided into 6 (n = 6)
groups and treated with fluvoxamine at doses of 25, 50,
100 or 200 mg/kg and ranitidine at a 50-mg/kg dose. The
last group received only distilled water as vehicle by oral
gavage. Six hours after drug administration, all rats in all
groups were killed with a high dose of thiopental sodium
(50 mg/kg, intra-peritoneal). The stomachs of all of the
rats were excised and were evaluated both macroscopi-
cally and biochemically, as described above.
Groups for this control experiment can be summarized as
follows:
Group 1: Fluvoxamine 25 mg/kg
Group 2: Fluvoxamine 50 mg/kg
Group 3: Fluvoxamine 100 mg/kg
Group 4: Fluvoxamine 200 mg/kg
Group 5: Ranitidine 50 mg/kg
Group 6: Intact group which received only distilled water.
Biochemical analyses
Biochemical investigation of stomach tissues
After the macroscopic analyses, the glutathione (GSH),
catalase (CAT), superoxide dismutase (SOD), myeloper-
oxidase (MPO), and malondialdehyde (MDA) enzyme
activities and levels in rat stomach tissues were deter-
mined. For this purpose stomachs of rats were frozen at -
80°C before until biochemical investigations. To prepare
the tissue homogenates, stomach tissues were ground
with liquid nitrogen in a mortar. The ground tissues (0.5
g each) were then treated with 4.5 mL of an appropriate
buffer. The mixtures were homogenized on ice using an
Ultra-Turrax homogenizer for 15 min. Homogenates were
filtered and centrifuged using a refrigerated centrifuge at
4°C. The supernatants were used for the determination of
the enzymatic activities. All assays were carried out at
room temperature in triplicate.
Total GSH determination
The amount of GSH in the gastric mucosa was measured
according to the method of Sedlak and Lindsay [37]. The
mucosal surface of the stomach was collected by scraping,
weighed, and then homogenized in 2 mL 50 mM Tris-HCl
buffer containing 20 mM EDTA and 0.2 mM sucrose, pH
7.5. The homogenate was immediately precipitated with
0.1 mL of 25% trichloroacetic acid, and the precipitate
was removed by centrifugation at 4200 rpm for 40 min at
4°C. The supernatant was used to determine GSH using
5,5'-dithiobis(2-nitrobenzoic acid. Absorbance was meas-
ured at 412 nm using a spectrophotometer. The results of
the GSH level in the gastric mucosa were expressed as
nanomoles per milligram tissue (nmol/mg tissue).
NO levels
Tissue NO levels were measured as total nitrite + nitrate
levels with the use of the Griess reagent as previously
described [38]. The Griess reagent consists of sulfanila-
mide and N-(1-napthyl)- ethylenediamine. The method is
based on a-two-step process. The first step is the conver-
sion of nitrate into nitrite using a nitrate reductase. The
second step is the addition of the Griess reagent, which
converts nitrite into a deep purple azo compound; photo-
metric measurement of absobance at 540 nm is due to the
fact that this azo chromophore accurately determines
nitrite concentration. NO levels were expressed as μmol/g.
MPO activity
MPO activity was measured according to the modified
method of Bradley et al. [39]. The homogenized samples
were frozen and thawed three times, and centrifuged at
1500 g for 10 min at 4°C. MPO activity in the supernatant
was determined by adding 100 mL of the supernatant to
1.9 mL of 10 mmol/L phosphate buffer (pH 6.0) and 1
mL of 1.5 mmol/L o-dianisidine hydrochloride contain-
ing 0.0005% (wt/vol) hydrogen peroxide. The changes in
absorbance at 450 nm of each sample were recorded on a
UV-vis spectrophotometer. MPO activity in gastric tissues
was expressed as minimoles per minute per milligram tis-
sue (mmol/min/mg tissue).
Determination of lipid peroxidation or MDA formation
The concentrations of gastric mucosal lipid peroxidation
were determined by estimating MDA using the thiobarbi-
turic acid test [40]. Briefly, the rat stomachs were promptly
excised and rinsed with cold saline. To minimize the pos-
sibility of interference of hemoglobin with free radicals,
any blood adhering to the mucosa was carefully removed.BMC Gastroenterology 2009, 9:36 http://www.biomedcentral.com/1471-230X/9/36
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The corpus mucosa was scraped, weighed, and homoge-
nized in 10 mL of 100 g/L KCl. The homogenate (0.5 mL)
was added to a solution containing 0.2 mL of 80 g/L
sodium lauryl sulfate, 1.5 mL of 200 g/L acetic acid, 1.5
mL of 8 g/L 2-thiobarbiturate, and 0.3 mL distilled water.
The mixture was incubated at 98°C for 1 h. Upon cooling,
5 mL of n-butanol:pyridine (15:l) was added. The mixture
was vortexed for 1 min and centrifuged for 30 min at 4000
rpm. The absorbance of the supernatant was measured at
532 mn. A standard curve was generated using 1,1,3,3-
tetramethoxypropane. The recovery was over 90%. The
results were expressed as nanomoles MDA per gram wet
tissue (nmol/mg tissue).
Statistical analyses
Data are presented as means ± Standard Error (SE).
Enzyme activity and ulcer score results were subjected to
one-way ANOVA, with presence of negative and positive
controls, using SPSS 11.0 software. Differences among
groups were attained using least significant difference
(LSD) option, and significance was declared at P < 0.05.
Results
Indomethacin-induced ulcer test
Macroscopic lesions with evident borderlines in various
forms and sizes were dispersed irregularly on all stomach
surfaces in the stomach tissue of the control rats which
received indomethacin. Hyperemia was more evident in
the control group which received indomethacin when
compared to the groups which received fluvoxamine and
ranitidine. The severity of hyperemia was paralleled with
an increase in ulcers. As seen in Table 1, a decrease in ulcer
occurrence of 48%, 67.5%, 82.1%, and 96.1% occurred in
the stomachs of rat groups which received 25, 50, 100,
and 200 mg/kg fluvoxamine. The antiulcer effect of 50
mg/kg ranitidine was 86.5%. No differences were
observed in the absence of indomethacin treatment fol-
lowing any dose of fluvoxamine or ranitidine.
Results of biochemical analyses
All doses of fluvoxamine and ranitidine significantly
decreased the amount of GSH in stomach tissues when
compared to healthy intact rats, when administered alone
However, a 25 mg/kg dose of fluvoxamine did not affect
the levels of other parameters that we measured (MDA,
NO and MPO) when compared to healthy intact rats
(Table 2). At doses of 50, 100 and 200 mg/kg fluvoxamine
significantly decreased the levels of MDA and MPO and
increased the level of NO in stomach tissue when com-
pared to intact healthy rat group. Similar changes were
observed in tissues from ranitidine-treated rats.
Indomethacin application significantly decreased the lev-
els of antioxidant parameters, GSH and NO, and signifi-
cantly increased the levels of oxidant parameters, MPO
and MDA. All doses of fluvoxamine and ranitidine which
were co-administrated with indomethacin reversed the
negative effects of indomethacin on stomach tissue (Fig-
ures 1, 2, 3, 4).
Table 1: Effects of flovoksamine (FLU) and ranitidine (RAN) on indomethacin (IND) induced ulcers in rats.
Drugs Dose
(mg/kg)
Number of animals Ulcer area (mm2) Antiulcer effect (%) P
FLU 25 < 0.05
+ 6 15.3 ± 1.5 48.5
IND 25
FLU 50 < 0.02
+ 6 9.7 ± 0.9 67.5
IND 25
FLU 100 < 0.01
+ 6 5.3 ± 0.4 82.1
IND 25
FLU 200 < 0.001
+ 6 1.2 ± 0.02 96.1
IND 25
RAN 50 < 0.001
+ 6 4.0 ± 0.6 86.5
IND 25
Indomethacin (Control) 25 6 29.7 ± 2.6 - -BMC Gastroenterology 2009, 9:36 http://www.biomedcentral.com/1471-230X/9/36
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Discussion
In this study, the antiulcer effect of fluvoxamine was
investigated in rats using an indomethacin-induced ulcer
model. In addition, the effect of fluvoxamine on oxidant
and antioxidant parameters in rat stomach tissue was eval-
uated. Fluvoxamine was found to significantly inhibit
indomethacin-induced ulcers at all doses tested. The anti-
ulcer capacity of fluvoxamine was determined to be dose-
dependent; 200 mg/kg dose of fluvoxamine inhibited
indomethacin-induced ulcers more significantly than did
ranitidine.
Indomethacin has been shown to produce higher gastric
damage in rats when compared to other NSAIDs [41]. For
this reason, it has become the preferred drug for inducing
ulcer models. In many experimental studies, antidepres-
sant drugs have been shown to produce antiulcer effects
by reducing histamine secretion from mast cells, inhibit-
ing gastric acid secretion, and blockading leukotriene
(LTC4, D4, E4) receptors [42,43]. Apart from these factors,
the important primary factor in indomethacin-induced
gastric damage is ROS mediated lipid peroxidation [44]
Fluvoxamine, a SSRI drug, inhibits the CYP 1A2 enzyme
[26], which is known to produce ROS [27]. For this rea-
son, we investigated fluvoxamine effects on GSH, NO,
MPO, and MDA activities in the indomethacin-induced
ulcerous stomach tissue of rats, as a first approach at
investigating the mechanism behind the antiulcer effects
of fluvoxamine.
The roles of toxic oxygen radicals were determined in eti-
opathogenesis of indomethacin- induced gastric damage
[44]. Antioxidant parameters have been shown to be
reduced in stomach tissue damaged by indomethacin
[45]. Our experimental results are in line with these previ-
ous data. Fluvoxamine significantly prevented the nega-
tive effect of indomethacin on gastric GSH levels at all
doses used. The gastric GSH level was highest at the most
Effects of fluvoxamine (FLU)+indomethacin (IND), ranitidine (RAN)+indomethacin (IND) and alone indomethacin (IND) on  tGSH levels in the stomach tissues of rats Figure 1
Effects of fluvoxamine (FLU)+indomethacin (IND), ranitidine (RAN)+indomethacin (IND) and alone 
indomethacin (IND) on tGSH levels in the stomach tissues of rats. *Significant at p < 0.05 when compared to control.BMC Gastroenterology 2009, 9:36 http://www.biomedcentral.com/1471-230X/9/36
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effective dose of fluvoxamine. In addition, the GSH level
was lower at the 25 mg/kg dose, which had the lowest
antiulcer effect. All doses of fluvoxamine and ranitidine
also increased the GSH content significantly when admin-
istered in the absence of an indomethacin treatment. Our
experimental results and the previously published litera-
ture data indicate that there is an important relationship
between gastric GSH levels and ulcer severity. In tissue,
GSH and GSH-related enzymes are accepted as important
protective agents due to their antioxidant properties [46].
NSAID treatment causes reduction of these antioxidants
and initiates lipid peroxidation in stomach tissue, result-
ing in gastric damage [47]. All doses of fluvoxamine used
in our experiment (25, 50, 100, and 200 mg/kg) restored
the GSH levels in gastric tissue which were decreased by
indomethacin; this affected the antioxidant defense sys-
tem positively and reduced gastric damage. GSH detoxi-
fies hydrogen peroxide and/or organic acids chemically;
hydrogen peroxide accumulates in the absence of GSH
[48]. In the presence of transition metals such as Fe and
Cu, hydrogen peroxide reacts with superoxide resulting in
the formation of hydroxyl radical, the most reactive and
cytotoxic form of ROS [49].
In stomach tissue damaged by indomethacin, NO levels
have been shown to be reduced [50]. NO is known to
modulate acid levels, gastric mucus secretion, and blood
flow in gastric tissues [51]. NO has also been reported to
prevent membrane lipid peroxidation [52]. NO levels
have been shown to be reduced in damaged stomach tis-
sue [53]. Khattab et al reported that L-arginine almost
completely protects against indomethacin-induced gastric
ulceration. The mechanism for this is independent of any
modulation of acid secretion, mucin content, or pepsin
activity, but appears to occur via maintenance of mucosal
NO. This study also demonstrated that the NO synthase
inhibitor, L-NAME, aggravated ulcer formation [54]. In
Effects of fluvoxamine (FLU)+indomethacin (IND), ranitidine (RAN)+indomethacin (IND) and alone indomethacin (IND) on  NO levels in the stomach tissues of rats Figure 2
Effects of fluvoxamine (FLU)+indomethacin (IND), ranitidine (RAN)+indomethacin (IND) and alone 
indomethacin (IND) on NO levels in the stomach tissues of rats. *Significant at p < 0.05 when compared to control.BMC Gastroenterology 2009, 9:36 http://www.biomedcentral.com/1471-230X/9/36
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the current study, all doses of fluvoxamine, which exerted
a significant antiulcer effect, also increased gastric NO lev-
els significantly when compared to the control. A parallel
between the decrease of NO levels and severity of gastric
damage was also noted. Therefore, we can conclude that
the antiulcer effects of fluvoxamine could be mitigated by
L-NAME application, similar to the effect potentiated by
L-arginine application. In our experiment, ranitidine was
also shown to increase NO levels significantly when com-
pared to control. Our results are in line with those
reported previously in the literature [30].
Indomethacin has been shown to produce damage via
increasing mucosal MPO and MDA levels in gastric tissue
[55]. MPO exists in polymorph nuclear leukocyte cells
(PNL) and catalyses the formation of toxic hypochlorous
acid (HOCl) from hydrogen peroxide [56]. In addition,
polymorph nuclear leukocytes (PNLs) excessively pro-
duce superoxide anion (O2-) and hydroxyl radical (OH-),
which are free oxygen radicals [57]. Excessive production
of MPO and other reactive radicals cause oxidative dam-
age; oxidative damage is represented by measuring lipid
peroxidation levels [58]. Lipid peroxidation is an impor-
tant reason for cell membrane damage; MDA is the end
product of lipid peroxidation and is used to determine
lipid peroxidation levels [59]. Gastric MPO and MDA
increases resulting from indomethacin application were
decreased by fluvoxamine. Fluvoxamine decreased levels
of oxidant parameters and increased those of antioxidant
parameters not only in rats given indomethacin, but also
in healthy, intact rats.
CYP1A2 enzymes are also known to produce ROS [27].
Fluvoxamine inhibited these enzymes [26]. So above
mentioned antioxidative effects of fluvoxamine may also
be related to inhibition of CYP1A2 enzymes.
Effects of fluvoxamine (FLU)+indomethacin (IND), ranitidine (RAN)+indomethacin (IND) and alone indomethacin (IND) on  MPO levels in the stomach tissues of rats Figure 3
Effects of fluvoxamine (FLU)+indomethacin (IND), ranitidine (RAN)+indomethacin (IND) and alone 
indomethacin (IND) on MPO levels in the stomach tissues of rats. *Significant at p < 0.05 when compared to control.BMC Gastroenterology 2009, 9:36 http://www.biomedcentral.com/1471-230X/9/36
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Effects of fluvoxamine (FLU)+indomethacin (IND), ranitidine (RAN)+indomethacin (IND) and alone indomethacin (IND) on  MDA levels in the stomach tissues of rats Figure 4
Effects of fluvoxamine (FLU)+indomethacin (IND), ranitidine (RAN)+indomethacin (IND) and alone 
indomethacin (IND) on MDA levels in the stomach tissues of rats. *Significant at p < 0.05 when compared to control.
Table 2: Effects of fluvoxamine (FLU) alone and ranitidine (RAN) alone on tGSH, NO, MPO, and MDA levels in the stomach tissues of 
rats.
Drugs Dose
(mg/kg)
tGSH MDA NO MPO
FLU 25 14.9 ± 0.6 2.1 ± 0.3 80.4 ± 6.3 1.0 ± 0.02
FLU 50 15.1 ± 0.3* 1.8 ± 0.2* 95.2 ± 4.5* 0.8 ± 0.04*
FLU 100 17.1 ± 0.8* 1.7 ± 0.3* 99.7 ± 5.7* 0.5 ± 0.03*
FLU 200 18.3 ± 0.6* 1.6 ± 0.2* 105.1 ± 5.2* 0.4 ± 0.01*
RAN 50 15.8 ± 0.4* 2.1 ± 0.5* 96.8 ± 4.7* 0.6 ± 0.03*
Intact (Control) - 12.7 ± 0.2 2.3 ± 0.4 83.4 ± 3.6 1.1 ± 0.05
*Significant at p < 0.05 when compared to intact control.BMC Gastroenterology 2009, 9:36 http://www.biomedcentral.com/1471-230X/9/36
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Gastric side effects of SSRI drugs have been reported [31].
The combined usage of SSRI drugs and indomethacin has
been reported to cause gastrointestinal bleeding [60].
However, several novel arylpiperazine serotonin 1A recep-
tor (5HT1-A) agonists, developed as anxiolytics, were
shown to have antisecretory and gastroprotective effects in
rats [61]. In addition, 5HT1-A antagonists increase the
potency of serotonin-related contractions in stomach tis-
sue [62], while the 5HT1-A agonist buspiron decreases
stomach and intestinal distension [63]. In the light of this
literature, it can be hypothesized that the antiulcer effect
of fluvoxamine may be related to a stimulation of 5HT1-
A receptors, but further detailed studies are required to
clarify this point.
Conclusion
In conclusion, we report that fluvoxamine has antiulcer
effects. Indomethacin causes gastric damage by not only
inhibiting cyto-protective PG synthesis, but also by affect-
ing oxidant and antioxidant mechanisms, such as GSH,
NO, MPO, and MDA. Fluvoxamine appears to exert its
antiulcer effects by activation of antioxidant mechanisms
and inhibition of toxic oxidant mechanisms in stomach
tissues.
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